Stocktoria
Rapport Therapeutics, Inc. RAPP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-06-07
Rapport Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $94.8M | $60.9M | $28.0M |
| Operating income | -$125.1M | -$83.1M | -$36.2M |
| Income tax | $0 | $0 | $10,000 |
| Net income | -$111.5M | -$78.3M | -$34.8M |
| EPS (diluted) | $-2.86 | $-3.78 | $-23.10 |
| Operating cash flow | -$87.5M | -$64.8M | -$27.2M |
| Free cash flow | -$88.1M | -$67.2M | -$28.8M |
| Cash & equivalents | $52.6M | $56.8M | $70.2M |
| Total assets | $512.4M | $314.9M | $155.4M |
| Total liabilities | $27.8M | $9.5M | $14.5M |
| Shareholders' equity | $484.7M | $305.4M | -$25.6M |
Source: SEC EDGAR filings · CIK 0002012593 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.